Kirby McInerney LLP Announces Investigation Against Zynex, Inc. (ZYXI) on Behalf of Investors
1. Zynex faces investigation for potential securities law violations. 2. Fourth quarter results showed revenue shortfall due to payment delays. 3. Tricare has suspended payments, representing 20-25% of Zynex's revenue. 4. Shares dropped by approximately 51% following the announcement. 5. Legal scrutiny may impact investor confidence and future earnings.